Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients.

Abstract

BACKGROUND:

Although Helicobacter pylori infection is believed to be the main cause of chronic gastritis, a US clinical trial investigating the long-term effects of lansoprazole as maintenance therapy for erosive esophagitis revealed a surprisingly high prevalence (over 90%) and severity of chronic gastritis in H. pylori-negative subjects.

GOALS:

This study aims to compare prevalence and severity of chronic gastritis of the body and antrum in H. pylori-negative subjects with erosive esophagitis, nonerosive reflux disease, or functional dyspepsia from several trials.

STUDY:

Pretreatment gastric histology was compared in 1595 H. pylori-negative subjects with erosive esophagitis (>or= grade 2; n=196), nonerosive reflux disease (n=688), or functional dyspepsia (n=711) who participated in US Takeda-sponsored lansoprazole trials.

RESULTS:

Pretreatment histology data from US clinical studies showed that 67.5% and 75.0% of H. pylori-negative adult subjects with erosive esophagitis had moderate or severe body and antral chronic gastritis, respectively. Chronic gastritis was also observed in H. pylori-negative subjects with nonerosive reflux disease or functional dyspepsia, although prevalence was significantly less (P<0.001) than in erosive esophagitis.

CONCLUSIONS:

Chronic gastritis in H. pylori-negative subjects is more common than previously appreciated. These results highlight the need for better characterization of gastric mucosal histology in these gastrointestinal disorders.

• Authors: David A Peura, Marian M Haber, Barbara Hunt, Stuart Atkinson
• Journal: Journal of clinical gastroenterology (J Clin Gastroenterol) Vol. 44 Issue 3 Pg. 180-5 (Mar 2010) ISSN: 1539-2031 [Electronic] United States
• PMID: 19687753 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents
• Lansoprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (therapeutic use)
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Ulcer Agents (therapeutic use)
• Chronic Disease
• Clinical Trials as Topic
• Dyspepsia (drug therapy, etiology, physiopathology)
• Esophagitis (drug therapy, etiology, physiopathology)
• Female
• Gastric Mucosa (pathology)
• Gastritis (epidemiology, etiology)
• Gastroesophageal Reflux (drug therapy, etiology, physiopathology)
• Humans
• Lansoprazole
• Male
• Middle Aged
• Prevalence
• Retrospective Studies
• Severity of Illness Index
• Young Adult